• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1992 Fiscal Year Final Research Report Summary

Peptide Histidine Isoleucine (PHI) in the Respiratory Tract

Research Project

Project/Area Number 02670336
Research Category

Grant-in-Aid for General Scientific Research (C)

Allocation TypeSingle-year Grants
Research Field Respiratory organ internal medicine
Research InstitutionGunma University School of Medicine

Principal Investigator

KUROSAWA Motohiro  Gunma University School of Medicine First Department of Internal Medicine Lecturer in Medicine, 医学部, 助手 (10170119)

Co-Investigator(Kenkyū-buntansha) HISADA Takeshi  Gunma University School of Medicine First Department of Internal Medicine Postgr
Project Period (FY) 1990 – 1992
KeywordsPHI / VIP / immunoreactivity / respiratory tract / airway resistance / superoxide anion / inflammatory cells / leukotriene C_4 / rat / guinea pig
Research Abstract

(1) A high titer of peptide histidine isoleucine (PHI) antiserum which did not react with vasoactive intestinal peptide (VIP) was obtained from a rabbit immunized with rat PHI and rat PHI radioimmunoassay was established with this antiserum. Tracheas, extrapulmonary bronchi and lungs were dissected from rats sacrificed by microwave irradiation. They were homoginized with 0.5 N acetic acid and centrifuged. Lyophilized supernates were used as samples for the radioimmunoassay. PHI immunoreactivity occurred more in the central airways than in the peripheral ones. VIP immunoreactivity in rat respiratory tracts, assayed simultaneously by radioimmunoassay using commercialized VIPantiserum, was as strong as that of PHI, suggesting that PHI and VIP may be produced from the same precursor at the ratio of 1:1 in rat respiratory tracts.
(2) Intravenous administration of VIP or PHI reduced dynamic respiratory resistance; however, the effect was significantly less than that of isoprenaline. VIP and P … More HI inhibited the increase in dynamic respiratory resistance by intravenous administration of histamine in a dose-dependent manner, suggesting that VIP and PHI may be involved in the pathogenesis of airway hyperresponsiveness through inhibiting the effect of mediator release on the airway.
(3) VIP inhibited superoxide anion production in a dose- dependent manner by the activated peripheral blood neutrophils, mononuclear cells and also by the human monoblast cell line U937, the capacity of which for superoxide anion formation was induced by the pretreatment of interferon-gamma. 3x10^<-6> M VIP also inhibited superoxide anion generation by the activated peripheral blood eosinophils and alveolar macrophages obtained by bronchoalveolar lavage, suggesting VIP may serve as an endogenous modulator of inflammatory reactions in the respiratory tract.
(4) A high titer of PHI antiserum which did not react with VIP was obtained from a rabbit immunized with rat PHI and PHI like immunoreactivity in the respiratory tract from guinea pigs was measured by radioimmunoassay. Tracheas, extrapulmonary bronchi and lungs were dissected and treated by microwave irradiation. They were homogenized with 0.5 N acetic acid and centrifuged. Lyophilized supernates were used as samples for the radioimmunoassay. PHI like immunoreactivity was present more in the central airways than in the peripheral ones. Intravenous administration of leukotriene C_4 reduced significantly PHI like immunoreactivity in the tracheas and the extrapulmonary bronchi in parallel with the significant increase of dynamic respiratory resistance. Less

  • Research Products

    (7 results)

All Other

All Publications (7 results)

  • [Publications] Kurosawa M., Ishizuka T.: "Neuropeptides in the respiratory tract. Drug News & Perspective" 3(2). 79-84 (1990)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Ishizuka T., Kurosawa M.: "Basic study of peptide histidine isoleucine (PHI) immunoreactivity in rat respiratory tract. Jpn.J.Allergol." 39(7). 577-586 (1990)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Ishizuka T., Kurosawa M.: "Measurement of VIP immunoreactivity. Clinical Immunology" 22(Suppl.15). 114-120 (1990)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Ishizuka T., Kurosawa M.: "Measurement of VIP immunoreactivity in the respiratory tract from guinea pigs-basic investigation about VIP extraction procedures. Jpn.J.Inflammation" 10(5). 379-382 (1990)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Aoki S., Kurosawa M., Ishizuka T., Mori M.: "Inhibitory effect of vasoactive intestinal peptide (VIP) and peptide histidine isoleucine (PHI) on bronchoconstriction in guinea pigs. Jpn.J.Thoracic Diseases" 30(11). 1946-1950 (1992)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Ishizuka T., Kurosawa M., Hanawa K., Aoki S., Kobayashi H., Mori M.: "Inhibitory effects of vasoactive intestinal peptide on superoxide anion generation from stimulated human inflammatory cells. Jpn.J.Allergol." 41(4). 504-511 (1992)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Hisada T., Ishizuka T., Kurosawa M.: "Leukotriene C_4-induced decrease of peptide histidine isoleucine (PHI) like immunoreactivity in the respiratory tract from guinea pigs. Jpn.J.Clin.Immun." 16(2).

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1994-03-24  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi